Quitting rates of novel tobacco products in a model smoking cessation clinic (SCC)

<bold>Introduction:</bold> While the consumption of conventional tobacco products (CTP) is slowly decreasing, novel tobacco products (NTP) such as electronic and heated cigarettes are gaining popularity. Although NTP may be less harmful, abstinence from all tobacco products should be the final goal. Therefore, cessation guidelines should be produced for ΝTP. However, data regarding NTP cessation methods are few. <bold>Aim:</bold> Tο study the quit rates of NTP in a SCC settings. <bold>Methods:</bold> We conducted a cross-sectional study in the outpatient SCC of Evangelismos Hospital during November 2022-2023. A specialized psychologist and a respiratory physician provided behavioural and pharmaceutical treatment in 5 sessions in both groups. Demographics, comorbidities, addiction, previous attempts and readiness to quit were recorded from CTP and NTP users. <bold>Results:</bold> Data of 118 pts are shown at Table 1&2. <list><list-item><label>•</label> Most of NTP smokers were dual users and highly addicted (62.7%). </list-item><list-item><label>•</label> Both groups had respiratory (Asthma CP:19.5%vs NTP:34.3% & COPD CTP:12.2%) and mental health comorbidities (depression/ anxiety,CTP:26.8%vs NTP: 22.9%). </list-item><list-item><label>•</label> A high percentage were motivated to quit (CP: 82%vs NTP:69.1%) and had previously attempted to quit (CP: 81.4%vs NTP: 74.6%). </list-item><list-item><label>•</label> Smoking cessation rates at 3 months were high in both groups (CP:63.6% vs NTP:74.5%). </list-item></list> <bold>Conclusion:</bold> The combination of behavioral and pharmaceutical therapy is effective as cessation method for NTP. <fig><object-id>erj;64/suppl_68/PA507/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>